Stifel Nicolaus Sticks to Their Buy Rating for Tocagen Inc

By Carrie Williams

In a report released yesterday, Thomas Shrader from Stifel Nicolaus reiterated a Buy rating on Tocagen Inc (NASDAQ: TOCA), with a price target of $24. The company’s shares opened today at $11.16.

According to, Shrader is a 5-star analyst with an average return of 25.2% and a 53.7% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Threshold Pharmaceuticals, and Inovio Pharmaceuticals.

Tocagen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $21.50.

Based on Tocagen Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $11K and GAAP net loss of $9.07 million. In comparison, last year the company earned revenue of $14K and had a GAAP net loss of $8.01 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which focuses on developing product candidates designed to activate a patient’s immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E.